# Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer

> **NCT06677762** · — · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** Irreversible electroporation

## Key facts

- **NCT ID:** NCT06677762
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677762, "Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06677762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*